Annual Accounts Receivable
$144.16 M
-$21.34 M-12.90%
31 December 2023
Summary:
Supernus Pharmaceuticals annual accounts receivable is currently $144.16 million, with the most recent change of -$21.34 million (-12.90%) on 31 December 2023. During the last 3 years, it has risen by +$3.28 million (+2.33%). SUPN annual accounts receivable is now -12.90% below its all-time high of $165.50 million, reached on 31 December 2022.SUPN Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$145.41 M
-$7.09 M-4.65%
30 September 2024
Summary:
Supernus Pharmaceuticals quarterly accounts receivable is currently $145.41 million, with the most recent change of -$7.09 million (-4.65%) on 30 September 2024. Over the past year, it has increased by +$3.64 million (+2.57%). SUPN quarterly accounts receivable is now -12.14% below its all-time high of $165.50 million, reached on 31 December 2022.SUPN Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SUPN Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -12.9% | +2.6% |
| 3 y3 years | +2.3% | +8.8% |
| 5 y5 years | +40.1% | +67.7% |
SUPN Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -12.9% | +2.3% | -12.1% | +8.8% |
| 5 y | 5 years | -12.9% | +65.1% | -12.1% | +67.7% |
| alltime | all time | -12.9% | -12.1% |
Supernus Pharmaceuticals Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $145.41 M(-4.6%) |
| June 2024 | - | $152.49 M(+3.2%) |
| Mar 2024 | - | $147.73 M(+2.5%) |
| Dec 2023 | $144.16 M(-12.9%) | $144.16 M(+1.7%) |
| Sept 2023 | - | $141.76 M(+3.8%) |
| June 2023 | - | $136.56 M(-4.9%) |
| Mar 2023 | - | $143.57 M(-13.3%) |
| Dec 2022 | $165.50 M(+11.1%) | $165.50 M(+0.9%) |
| Sept 2022 | - | $164.09 M(+3.8%) |
| June 2022 | - | $158.06 M(+8.9%) |
| Mar 2022 | - | $145.15 M(-2.5%) |
| Dec 2021 | $148.93 M(+5.7%) | $148.93 M(+11.4%) |
| Sept 2021 | - | $133.68 M(-2.6%) |
| June 2021 | - | $137.28 M(+8.0%) |
| Mar 2021 | - | $127.06 M(-9.8%) |
| Dec 2020 | $140.88 M(+61.3%) | $140.88 M(+5.8%) |
| Sept 2020 | - | $133.11 M(+5.2%) |
| June 2020 | - | $126.56 M(+6.2%) |
| Mar 2020 | - | $119.19 M(+36.5%) |
| Dec 2019 | $87.33 M(-15.1%) | $87.33 M(+0.7%) |
| Sept 2019 | - | $86.70 M(+2.5%) |
| June 2019 | - | $84.56 M(+5.8%) |
| Mar 2019 | - | $79.95 M(-22.3%) |
| Dec 2018 | $102.92 M(+56.9%) | $102.92 M(+32.4%) |
| Sept 2018 | - | $77.75 M(+3.9%) |
| June 2018 | - | $74.84 M(+10.3%) |
| Mar 2018 | - | $67.86 M(+3.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2017 | $65.59 M(+57.9%) | $65.59 M(+16.8%) |
| Sept 2017 | - | $56.17 M(+9.8%) |
| June 2017 | - | $51.16 M(+31.6%) |
| Mar 2017 | - | $38.88 M(-6.4%) |
| Dec 2016 | $41.53 M(+60.3%) | $41.53 M(+14.7%) |
| Sept 2016 | - | $36.22 M(+5.7%) |
| June 2016 | - | $34.28 M(+11.8%) |
| Mar 2016 | - | $30.65 M(+18.3%) |
| Dec 2015 | $25.91 M(+50.0%) | $25.91 M(+9.8%) |
| Sept 2015 | - | $23.60 M(+31.9%) |
| June 2015 | - | $17.90 M(-7.1%) |
| Mar 2015 | - | $19.27 M(+11.6%) |
| Dec 2014 | $17.27 M(+241.7%) | $17.27 M(+12.9%) |
| Sept 2014 | - | $15.30 M(+41.0%) |
| June 2014 | - | $10.85 M(+11.6%) |
| Mar 2014 | - | $9.72 M(+92.4%) |
| Dec 2013 | $5.05 M(>+9900.0%) | $5.05 M(-29.9%) |
| Sept 2013 | - | $7.21 M(+1242.3%) |
| June 2013 | - | $537.00 K(-67.5%) |
| Mar 2013 | - | $1.65 M(>+9900.0%) |
| Dec 2012 | $11.00 K(>+9900.0%) | $11.00 K(-97.8%) |
| Sept 2012 | - | $500.00 K(>+9900.0%) |
| Dec 2011 | $0.00(-100.0%) | $0.00(-100.0%) |
| Sept 2011 | - | $3.98 M(+8940.9%) |
| Dec 2010 | $44.00 K(-98.7%) | $44.00 K(-98.5%) |
| Sept 2010 | - | $3.03 M(-11.0%) |
| Dec 2009 | $3.41 M(+49.7%) | $3.41 M |
| Dec 2008 | $2.28 M | - |
FAQ
- What is Supernus Pharmaceuticals annual accounts receivable?
- What is the all time high annual accounts receivable for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals annual accounts receivable year-on-year change?
- What is Supernus Pharmaceuticals quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals quarterly accounts receivable year-on-year change?
What is Supernus Pharmaceuticals annual accounts receivable?
The current annual accounts receivable of SUPN is $144.16 M
What is the all time high annual accounts receivable for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high annual accounts receivable is $165.50 M
What is Supernus Pharmaceuticals annual accounts receivable year-on-year change?
Over the past year, SUPN annual accounts receivable has changed by -$21.34 M (-12.90%)
What is Supernus Pharmaceuticals quarterly accounts receivable?
The current quarterly accounts receivable of SUPN is $145.41 M
What is the all time high quarterly accounts receivable for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high quarterly accounts receivable is $165.50 M
What is Supernus Pharmaceuticals quarterly accounts receivable year-on-year change?
Over the past year, SUPN quarterly accounts receivable has changed by +$3.64 M (+2.57%)